# REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

> **NCT03515629** · PHASE3 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** REGN2810/ipi
- **DRUG:** REGN2810/chemo/ipi
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03515629
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-02
- **Primary completion:** 2021-07-29
- **Final completion:** 2021-07-29
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2022-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515629, "REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03515629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*